Maraviroc - ViiV Healthcare

Drug Profile

Maraviroc - ViiV Healthcare

Alternative Names: Celsentri; MVC; Selzentry; UK-427857

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer; University of California at San Francisco
  • Developer International Partnership for Microbicides; Pfizer; ViiV Healthcare
  • Class Antiretrovirals; Cyclohexanes; Small molecules; Triazoles
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • No development reported Hypertriglyceridaemia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 21 Apr 2017 Committee for Medicinal Products for Human Use (CHMP) of the EMA recommends approval of Maraviroc for HIV-1 infections (In adolescents, In children, Treatment-experienced) in European Union
  • 13 Feb 2017 Pharmacokinetics data from a phase I trial in healthy volunteers presented at the 24th Conference on Retroviruses and Opportunistic Infections
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertriglyceridaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top